Nutriband Inc. (NASDAQ: NTRB), a company primarily engaged in the development of transdermal pharmaceutical products, announced the appointment of Robert J. O'Neill to its Advisory Board. O'Neill, a former U.S. Navy SEAL with 16 years of service, including eight years with the Naval Special Warfare Development Group (SEAL Team Six), brings a unique perspective to the company as it advances its pipeline of abuse-deterrent transdermal products. His extensive military background, including participation in more than 400 combat missions, and his role as a New York Times best-selling author and advocate for expanding veterans' access to emerging health treatments, position him as a valuable asset to Nutriband's executive team.
O'Neill's appointment comes at a critical time for Nutriband as it seeks to bring its lead product, AVERSA Fentanyl, to market. If approved, AVERSA Fentanyl would be the world's first and only abuse-deterrent fentanyl patch. This innovative product incorporates the company's proprietary AVERSA abuse-deterrent technology, which can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure to drugs with abuse potential. The potential approval of AVERSA Fentanyl could significantly impact the opioid crisis by providing a safer option for pain management.
The addition of O'Neill to the Advisory Board is a strategic move that underscores Nutriband's commitment to addressing the opioid epidemic. O'Neill's advocacy for veterans' access to emerging treatments aligns with the company's mission to develop products that improve patient safety. His insights and leadership will support Nutriband's executive team on strategy, growth, and execution as the company navigates the regulatory landscape and works towards commercializing its pipeline. For more information on Nutriband, visit their website at www.nutriband.com.
InvestorWire, a specialized communications platform, distributed the full press release, which can be viewed at https://ibn.fm/WuoNR. InvestorWire is part of the Dynamic Brand Portfolio at IBN, offering wire-grade press release syndication and editorial syndication to over 5,000 outlets, along with press release enhancement and social media distribution. For more details, visit InvestorWire. The latest news and updates relating to NTRB are available at https://ibn.fm/NTRB.
